Abnova Taiwan Corp Asset Resilience Ratio
Abnova Taiwan Corp asset resilience ratio. Abnova Taiwan Corp (4133) has an Asset Resilience Ratio of 0.07% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Abnova Taiwan Corp defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Abnova Taiwan Corp (2008–2025)
Asset resilience ratio of Abnova Taiwan Corp from 2008 to 2025. This chart shows how Abnova Taiwan Corp's Asset Resilience Ratio has changed over time. Read debt load of Abnova Taiwan Corp for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Abnova Taiwan Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 4133 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$886.00K | 0.07% |
| Total Liquid Assets | NT$886.00K | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Abnova Taiwan Corp maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Abnova Taiwan Corp Industry Peers by Asset Resilience Ratio
Compare Abnova Taiwan Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Abnova Taiwan Corp Asset Resilience Ratio by Year (2008–2025)
Abnova Taiwan Corp asset resilience ratio by year from 2008 to 2025. The table below shows the annual Asset Resilience Ratio data for Abnova Taiwan Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.07% | NT$880.00K ≈ $27.72K |
NT$1.33 Billion ≈ $41.82 Million |
+0.00pp |
| 2022-12-31 | 0.06% | NT$849.00K ≈ $26.75K |
NT$1.37 Billion ≈ $43.31 Million |
+0.02pp |
| 2021-12-31 | 0.04% | NT$545.00K ≈ $17.17K |
NT$1.28 Billion ≈ $40.42 Million |
+0.00pp |
| 2020-12-31 | 0.04% | NT$543.00K ≈ $17.11K |
NT$1.29 Billion ≈ $40.79 Million |
0.00pp |
| 2019-12-31 | 0.04% | NT$540.00K ≈ $17.01K |
NT$1.26 Billion ≈ $39.82 Million |
+0.00pp |
| 2018-12-31 | 0.04% | NT$537.00K ≈ $16.92K |
NT$1.29 Billion ≈ $40.80 Million |
+0.00pp |
| 2017-12-31 | 0.04% | NT$533.00K ≈ $16.79K |
NT$1.30 Billion ≈ $41.08 Million |
-5.50pp |
| 2016-12-31 | 5.54% | NT$69.11 Million ≈ $2.18 Million |
NT$1.25 Billion ≈ $39.33 Million |
-10.15pp |
| 2015-12-31 | 15.69% | NT$195.97 Million ≈ $6.17 Million |
NT$1.25 Billion ≈ $39.35 Million |
+15.65pp |
| 2014-12-31 | 0.04% | NT$522.00K ≈ $16.45K |
NT$1.31 Billion ≈ $41.21 Million |
0.00pp |
| 2013-12-31 | 0.04% | NT$517.00K ≈ $16.29K |
NT$1.29 Billion ≈ $40.49 Million |
+0.00pp |
| 2012-12-31 | 0.04% | NT$513.00K ≈ $16.16K |
NT$1.29 Billion ≈ $40.71 Million |
+0.00pp |
| 2011-12-31 | 0.04% | NT$508.00K ≈ $16.00K |
NT$1.36 Billion ≈ $42.70 Million |
0.00pp |
| 2010-12-31 | 0.04% | NT$504.00K ≈ $15.88K |
NT$1.33 Billion ≈ $42.03 Million |
-1.09pp |
| 2009-12-31 | 1.13% | NT$14.72 Million ≈ $463.73K |
NT$1.31 Billion ≈ $41.13 Million |
-0.07pp |
| 2008-12-31 | 1.20% | NT$10.26 Million ≈ $323.21K |
NT$857.02 Million ≈ $27.00 Million |
-- |
About Abnova Taiwan Corp
Abnova (Taiwan) Corporation engages in the research, development, manufacturing, and sales of monoclonal and multiclonal antibodies, proteins, medical diagnostic instruments, and testing reagents. The company's products portfolio includes SARS-CoV/CoV-2, DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems,… Read more